Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 9, 2016, Pages 1245-1255.e8

  Shah, Shailja C ^a   Colombel, Jean Frederic ^a   Sands, Bruce E ^a   Narula, Neeraj ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Clinical Trial; Endoscopic Remission; IBD; Inflammatory Bowel Disease

Indexed keywords

BIOLOGICAL PRODUCT; CORTICOSTEROID;

COLON MUCOSA; COLON RESECTION; COLONOSCOPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; HEALING; HUMAN; MUCOSAL HEALING; PROGNOSIS; PROSPECTIVE STUDY; REMISSION; REVIEW; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; INTESTINE MUCOSA; META ANALYSIS; PATHOLOGY; TREATMENT OUTCOME; WOUND HEALING;

COLITIS, ULCERATIVE; HUMANS; INTESTINAL MUCOSA; TREATMENT OUTCOME; WOUND HEALING;

EID: 84996843166     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.01.015     Document Type: Review

References (90)

1. 1 Lichtenstein, G.R., Rutgeerts, P., Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 16 (2010), 338–346.
2. 2 Pineton de Chambrun, G., Peyrin-Biroulet, L., Lemann, M., et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 7 (2010), 15–29.
3. 3 Rutter, M., Saunders, B., Wilkinson, K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126 (2004), 451–459.
4. 4 Dave, M., Loftus, E.V. Jr., Mucosal healing in inflammatory bowel disease: a true paradigm of success?. Gastroenterol Hepatol 8 (2012), 29–38.
5. 5 Falvey, J.D., Hoskin, T., Meijer, B., et al. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis 21 (2015), 824–831.
6. 6 Regueiro, M., Rodemann, J., Kip, K.E., et al. Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflamm Bowel Dis 17 (2011), 1008–1014.
7. 7 Hanauer, S.B., Sandborn, W.J., Kornbluth, A., et al. Delayed-release oral mesalamine at 4.8g/day for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 100 (2005), 2478–2485.
8. 8 Hanauer, S.B., Sandborn, W.J., Dallaire, C., et al. Delayed-release oral mesalamine 4.8 g/day compared to 2.4 g/day for treatment of mildly to moderately active ulcerative colitis: ASCEND I trial. Can J Gastroenterol 21 (2007), 827–834.
9. 9 Rizzello, F., Gionchetti, P., D'Arienzo, A., et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis. Aliment Pharmacol Ther 16 (2002), 1109–1116.
10. 10 Campieri, M., Adamo, S., Valpiani, D., et al. Oral beclometasone-dipropionate in the treatment of extensive and left-sided active ulcerative colitis. Aliment Pharmacol Ther 17 (2003), 1471–1480.
11. 11 Lofberg, R., Danielsson, A., Suhr, O., et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 110 (1996), 1713–1718.
12. 12 Regueiro, M., Loftus, E.V. Jr., Steinhart, A.H., et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis. Inflamm Bowel Dis 12 (2006), 979–994.
13. 13 Truelove, S.C., Witts, L.J., Cortisone in ulcerative colitis. Br Med J 2 (1955), 1041–1048.
14. 14 Truelove, S.C., Jewell, D.P., Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1 (1974), 1067–1070.
15. 15 Ardizzone, S., Maconi, G., Russo, A., et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55 (2006), 47–53.
16. 16 Paoluzi, O.A., Pica, R., Marcheggiano, A., et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 16 (2002), 1751–1759.
17. 17 Allez, M., Lemann, M., Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol 16 (2010), 2626–2632.
18. 18 Rutgeerts, P., Sandborn, W.J., Feagan, B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005), 2462–2476.
19. 19 Athanasiou, T., Al-Ruzzeh, S., Kumar, P., et al. Off-pump myocardial revascularization is associated with less incidence of stroke in elderly patients. Ann Thorac Surg 77 (2004), 745–753.
20. 20 Cornish, J., Tan, E., Teare, J., et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 56 (2007), 830–837.
21. 21 Egger, M., Davey Smith, G., Schneider, M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
22. 22 Higgins, J.P., Thompson, S.G., Deeks, J.J., et al. Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
23. 23 Armuzzi, A., Pugliese, D., Danese, S., et al. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis 20 (2014), 1368–1374.
24. 24 Oussalah, A., Evesque, L., Laharie, D., et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 105 (2010), 2617–2625.
25. 25 Ferrante, M., Vermeire, S., Fidder, H., et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2 (2008), 219–225.
26. 26 Jarnerot, G., Hertervig, E., Friis-Liby, I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005), 1805–1811.
27. 27 Sandborn, W.J., Rutgeerts, P., Feagan, B.G., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 137 (2009), 1250–1260.
28. 28 Inoue, T., Murano, M., Narabayashi, K., et al. The efficacy of oral tacrolimus in patients with moderate severe ulcerative colitis not receiving concomitant corticosteroid therapy. Intern Med 52 (2013), 15–20.
29. 29 Meucci, G., Fasoli, R., Saibeni, S., et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis 18 (2012), 1006–1010.
30. 30 Rismo, R., Olsen, T., Ciu, G., et al. The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn's disease. Scand J Gastroenterol 47 (2012), 1200–1210.
31. 31 Bokemeyer, B., Hommes, D., Gill, I., et al. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. J Crohns Colitis 6 (2012), 476–482.
32. 32 Guidi, L., Marzo, M., Andrisani, G., et al. Faecal calprotectin assay after induction with anti-tumour necrosis factor alpha agents in inflammatory bowel disease: prediction of clinical response and mucosal healing at one year. Dig Liver Dis 46 (2014), 974–979.
33. 33 Teisner, A.S., Ainsworth, M.A., Brynskov, J., Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: Danish single center experience. Scand J Gastroenterol 45 (2010), 1457–1463.
34. 34 Taxonera, C., Estelles, J., Fernandez-Blanco, I., et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther 33 (2011), 340–348.
35. 35 Laharie, D., Reffet, A., Belleannee, G., et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther 33 (2011), 714–721.
36. 36 Bessissow, T., Lemmens, B., Ferrante, M., et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 107 (2012), 1684–1692.
37. 37 Bitton, A., Peppercorn, M.A., Antonioli, D.A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 120 (2001), 13–20.
38. 38 Ohkusa, T., Nomura, T., Terai, T., et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 40 (2005), 1334–1342.
39. 39 Yokoyama, K., Kobayashi, K., Mukae, M., et al. Clinical study of the relation between mucosal healing and long-term outcomes in ulcerative colitis. Gastroenterol Res Pract 2013 (2013), 1–6.
40. 40 Laharie, D., Filippi, J., Roblin, X., et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther 37 (2013), 998–1004.
41. 41 Laharie, D., Bourreille, A., Branche, J., et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids. Lancet 380 (2012), 1909–1915.
42. 42 Subramaniam, K., Richardson, A., Dodd, J., et al. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy. Intern Med J 44 (2014), 464–470.
43. 43 Terao, S., Yamashiro, K., Tamura, I., et al. Antibiotic combination therapy for steroid withdrawal in steroid-dependent ulcerative colitis. Digestion 83 (2011), 198–203.
44. 44 Aratari, A., Papi, C., Clemente, V., et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis 40 (2008), 821–826.
45. 45 Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 96–109.
46. 46 Sandborn, W.J., van Assche, G., Reinisch, W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142 (2012), 257–265.
47. 47 Feagan, B.G., Rutgeerts, P., Sands, B.E., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369 (2013), 699–710.
48. 48 Jiang, X.L., Wang, H.H., Cui, H.F., Combined diosmectite and mesalazine treatment for mild-to-moderate ulcerative colitis. Med Sci Monit 21 (2015), 163–170.
49. 49 Lindberg, A., Eberhardson, M., Karlsson, M., et al. Long-term follow-up with granulocyte and monocyte apheresis retreatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol 10 (2010), 73–83.
50. 50 Bresci, G., Parisi, G., Mazzoni, A., et al. Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis. J Gastroenterol Hepatol 23 (2008), 1678–1682.
51. 51 Kamm, M.A., Lichtenstein, G.R., Sandborn, W.J., et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 57 (2008), 893–902.
52. 52 Kamm, M.A., Sandborn, W.J., Gassull, M., et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132 (2007), 66–75.
53. 53 Lichtenstein, G.R., Kamm, M.A., Boddu, P., et al. Effect of once- or twice-daily MMX mesalamine for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 5 (2007), 95–102.
54. 54 Plevy, S., Salzberg, B., Van Assche, G., et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 133 (2007), 1414–1422.
55. 55 Juliao, F., Marquez, J., Aristizabal, N., et al. Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a latin american referral population. Digestion 88 (2013), 222–228.
56. 56 Ardizzone, S., Cassinotti, A., Duca, P., et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 9 (2011), 483–489.
57. 57 Suzuki, Y., Motoya, S., Hanai, H., et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol 49 (2014), 283–294.
58. 58 Arias, M.T., Vande Casteele, N., Vermeire, S., et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 13 (2015), 531–538.
59. 59 Armuzzi, A., Pugliese, D., Danese, S., et al. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis 19 (2013), 1065–1072.
60. 60 Froslie, K.F., Jahnsen, J., Moum, B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133 (2007), 412–422.
61. 61 Gustavsson, A., Jarnerot, G., Hertervig, E., et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis—3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 32 (2010), 984–989.
62. 62 Kato, K., Ohkusa, T., Terao, S., et al. Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study. Aliment Pharmacol Ther 39 (2014), 949–956.
63. 63 Tursi, A., Elisei, W., Picchio, M., et al. Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first “real-life” experience in primary gastroenterology centers in Italy. Ann Gastroenterol 27 (2014), 369–373.
64. 64 Cabriada, J.L., Ibargoyen, N., Hernandez, A., et al. Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis. Dig Liver Dis 42 (2010), 432–435.
65. 65 Dai, C., Liu, W.X., Jiang, M., et al. Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy. PLoS One, 9, 2014, e110797.
66. 66 Parente, F., Molteni, M., Marino, B., et al. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis?. Am J Gastroenterol 105 (2010), 1150–1157.
67. 67 Yamamoto, T., Umegae, S., Matsumoto, K., Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis 16 (2010), 1905–1911.
68. 68 Colombel, J.F., Rutgeerts, P., Reinisch, W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141 (2011), 1194–1201.
69. 69 Tursi, A., Elisei, W., Picchio, M., et al. Managing ambulatory ulcerative colitis patients with infliximab: a long-term follow-up study in primary gastroenterology centers. Eur J Intern Med 25 (2014), 757–761.
70. 70 Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324–1338.
71. 71 Bouguen, G., Levesque, B.G., Pola, S., et al. Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis 20 (2014), 231–239.
72. 72 Travis, S., Feagan, B.G., Rutgeerts, P., et al. The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy. J Crohns Colitis 6 (2012), S250–S259.
73. 73 Reinisch, W., Van Assche, G., Befrits, R., et al. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis 6 (2012), 248–258.
74. 74 Schoepfer, A.M., Beglinger, C., Straumann, A., et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 15 (2009), 1851–1858.
75. 75 Sipponen, T., Savilahti, E., Kolho, K.L., et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 14 (2008), 40–46.
76. 76 Molander, P., af Bjorkesten, C.G., Mustonen, H., et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF alpha blocking agents. Inflamm Bowel Dis 18 (2012), 2011–2017.
77. 77 Ordas, I., Rimola, J., Garcia-Bosch, O., et al. Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: a prospective study. Gut 62 (2013), 1566–1572.
78. 78 Takashima, S., Kato, J., Hiraoka, S., et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. Am J Gastroenterol 110 (2015), 873–880.
79. 79 Sandborn, W.J., Colombel, J.F., D'Haens, G., et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 37 (2013), 204–213.
80. 80 Sandborn, W.J., Kamm, M.A., Lichtenstein, G.R., et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 26 (2007), 205–215.
81. 81 Rutgeerts, P., Vermeire, S., Van Assche, G., Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut 56 (2007), 453–455.
82. 82 Schroeder, K.W., Tremaine, W.J., Ilstrup, D.M., Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 317 (1987), 1625–1629.
83. 83 Travis, S.P., Schnell, D., Krzeski, P., et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity. Gut 61 (2012), 535–542.
84. 84 Travis, S.P., Schnell, D., Krzeski, P., et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 145 (2013), 987–995.
85. 85 Samaan, M.A., Mosli, M.H., Sandborn, W.J., et al. A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis 20 (2014), 1465–1471.
86. 86 Manginot, C., Baumann, C., Peyrin-Biroulet, L., An endoscopic Mayo score of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis. Gut 64 (2015), 1181–1182.
87. 87 Reinisch, W., Sandborn, W.J., Hommes, D.W., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised-controlled trial. Gut 60 (2011), 780–787.
88. 88 McDermott, E., Murphy, S., Keegan, D., et al. Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohns Colitis 7 (2013), 150–153.
89. 89 Zisman, T.L., Rubin, D.T., Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol 14 (2008), 2662–2669.
90. 90 Rubin, D.T., Huo, D., Kinnucan, J.A., et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis. Clin Gastroenterol Hepatol 11 (2013), 1601–1608.